She's 14 months old and needs a drug that costs $2.1 million to save her life

Ayah is 14 months old and suffers from spinal muscular atrophy, which affects one in 10,000 children.

(CNN)For the first few months of her life, Ayah Lundt was the picture of health.

Born in January last year at 8.3 pounds, the bubbly baby girl with dark curls and bright brown eyes hit all her developmental milestones.
By six months, she was crawling and trying new foods. Bananas and mushy broccoli were her favorites. Avocados, not so much.
    Then at nine months, her progress suddenly reversed. She could not lift her head while lying down, sit on her own or clap -- all things she'd excitedly done before. Her legs caved when she tried to crawl or stand. The key red flag came when she was unable to eat oatmeal with a spoon -- something she'd done numerous times.
      For a baby who loves her food, that was especially worrisome, her mother, Mary Mithika, told CNN by phone from their home in Bornholm, Denmark.
        Ayah was diagnosed with spinal muscular atrophy, a genetic disease found in one in 10,000 children born worldwide. She's now 14 months old and her parents are in a race against time to raise $2 million for a one-time, treatment before she turns 2.
        The treatment is called Zolgensma. At $2.1 million a dose, it's referred to as the world's most expensive drug.
          "I think about the cost every day, and it weighs me down," Mithika said through tears before taking a break to compose herself. "And then I look at Ayah and see her getting worse. As a parent, what would you do if you knew there's something out there that can save your child?"
          Mary Mithika and her daugher, Ayah.

          The drug could keep Ayah breathing

          Spinal muscular atrophy (SMA) is a progressive disease caused by a defective gene.
          The disease kills nerve cells and causes infants' muscles to waste away, which can lead to difficulty swallowing or breathing.
          As their muscles deteriorate, infants suffering from SMA develop finger tremors and a curved spine. They cannot stand or walk unaided, and most don't survive past early childhood due to respiratory failure.
          Zolgensma, the gene therapy treatment, is not a guaranteed cure. Ayah's mother says she will never walk again. But a one-time intravenous dose delivers a fully functional copy of the gene into the target nerve cells, altering the child's biology and improving muscle movement and function.
          The drug is not approved under universal health care in Denmark, the small Scandinavian nation of about 6 million people. So Ayah's parents are raising money to get her treated in the United States, where Zolgensma was approved in 2019 for use on children under age 2.
          Zolgensma is called the most expensive drug in the world.
          They've started talks with Boston Children's Hospital to get her treated there once they've raised enough money for the drug and the additional costs of tests and doctor visits in the US.
          The race to get the funds has spanned continents. Mithika, Ayah's mom, is from Kenya while her husband, Frank Lundt, is Danish. Friends and others from their respective homelands have helped by organizing fundraisers. But in a year marked by a pandemic and economic hardships, the family is struggling to meet their goal before Ayah turns 2.
          As of late March they had only raised about $60,000.
          "We just want what every parent wants -- the best for their child," Lundt said. Ayah has one other sibling, Amira, who's 2.
          "We were so excited about having another princess. She is perfect," he added. "She has always been such a happy child, even now with all this going on."

          At first, her parents didn't know much about the disease

          Ayah's parents recalled the day they found out she was suffering from a disease considered a leading genetic cause of death in infants and children.
          After they noticed her growing struggle to accomplish everyday tasks she'd done before, they mentioned it to a nurse making monthly visits to their home to check on the newborn's progress, a common practice in Denmark. She referred them to a doctor.
          On November 27, Ayah was diagnosed with spinal muscular atrophy type 2, which develops in infants between 6 and 12 months. Her mother and father sat motionless as the doctor listed the symptoms and long-term effects of a disease they did not fully understand.
          Frank Lundt, his wife, Mary Mithika, and their daughters, Ayah, 1, (seated) and Amira, 2.
          As soon as they got home, Mithika started crying while her husband turned to Google.
          "All we heard from the doctor was SMA, SMA," she said. "We had so many questions. We went on the internet to find out how bad it was. We called doctors we knew. We just wanted to find out as much as we c